GL Pharm Tech Balance Sheet Health
Financial Health criteria checks 5/6
GL Pharm Tech has a total shareholder equity of ₩19.6B and total debt of ₩15.6B, which brings its debt-to-equity ratio to 79.4%. Its total assets and total liabilities are ₩44.4B and ₩24.7B respectively.
Key information
79.4%
Debt to equity ratio
₩15.60b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩9.46b |
| Equity | ₩19.65b |
| Total liabilities | ₩24.72b |
| Total assets | ₩44.37b |
Recent financial health updates
Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?
Jul 23
Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?
Mar 30Recent updates
Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?
Jul 23Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% Higher
Mar 01Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?
Mar 30The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding On
Dec 15Financial Position Analysis
Short Term Liabilities: A204840's short term assets (₩21.5B) exceed its short term liabilities (₩14.5B).
Long Term Liabilities: A204840's short term assets (₩21.5B) exceed its long term liabilities (₩10.2B).
Debt to Equity History and Analysis
Debt Level: A204840's net debt to equity ratio (31.3%) is considered satisfactory.
Reducing Debt: A204840's debt to equity ratio has reduced from 320.7% to 79.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A204840 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A204840 has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.2% each year.